TORONTO, Aug. 31, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, Nasdaq: REUN) (“Reunion”), or (“the Company”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outcomes, today announced it has scheduled its 2022 Annual General Meeting of Shareholders for September 29, 2022 at 10:00 AM ET.

Source

Previous articleBright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome
Next articleFILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN HEALTH CANADA-APPROVED PSILOCYBIN CLINICAL TRIAL